Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (no linker) | ~3.37 kDa | Calculated from peptide sequence |
| Molecular weight (with linker) | ~3.65 kDa | Includes albumin-binding moiety |
| Appearance | White to off-white powder | Typically lyophilized |
| Solubility | Soluble in water | Also dissolves in aqueous buffers |
| Common synonyms | Modified GRF(1-29), DAC:GRF | Usage varies by source |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
That the notochord evolved de novo in chordates by combining development programs in new ways. That the notochord derives from a homologous muscular structure, the axochord, that was present in annelid-like ancestors of the chordates. Supported by gene expression patterns and identification of said muscular structures in various inveterates, but cannot fully rule out the possibility of homoplasy. Deciding between these two scenarios (or possibly another yet to be proposed) should be facilitated by much more thorough studies of gene regulatory networks in a wide spectrum of animals.
== Epidemiology == The prevalence of hemoglobin H disease mirrors that of the hemoglobinopathies. As a whole, they are most prevalent in individuals of Asian, African, and Mediterranean decent. There is a protective effect against malaria for individuals carrying thalassemia genes, which explains the high frequency of thalassemia within the worldwide population.
=== China === The Government of China provides the funding for dialysis treatment. There is a challenge to reach everyone who needs dialysis treatment because of the unequal distribution of health care resources and dialysis centers. There are 395,121 individuals who receive hemodialysis or peritoneal dialysis in China per year. The percentage of the Chinese population with Chronic Kidney Disease is 10.8%. The Chinese Government is trying to increase the amount of peritoneal dialysis taking place to meet the needs of the nation's individuals with Chronic Kidney Disease.
Sources: en.wikipedia.org
NH3 + 5-glutamyl-D-glutamyl-peptide The 3 substrates of this enzyme are L-glutamine, D-glutamine, and D-glutamyl-peptide, whereas its two products are NH3 and 5-glutamyl-D-glutamyl-peptide. This enzyme belongs to the family of transferases, specifically the aminoacyltransferases. The systematic name of this enzyme class is glutamine:D-glutamyl-peptide 5-glutamyltransferase. Other names in common use include D-glutamyl transpeptidase, and D-gamma-glutamyl transpeptidase. This enzyme participates in d-glutamine and d-glutamate metabolism.
Aagenaes syndrome Acroangiodermatitis (acroangiodermatitis of Mali, Mali acroangiodermatitis, Pseudo-Kaposi's sarcoma) Acrocyanosis Acute hemorrhagic edema of infancy (acute hemorrhagic edema of childhood, Finkelstein's disease, infantile postinfectious iris-like purpura and edema, medallion-like purpura, purpura en cocarde avec oedema, Seidlmayer syndrome) Arterial insufficiency ulcer (ischemic ulcer) Arteriosclerosis obliterans Bier spots Blueberry muffin baby Bonnet–Dechaume–Blanc syndrome (Wyburn–Mason syndrome) Bullous lymphedema Bullous small vessel vasculitis (bullous variant of small vessel vasculitis) Calciphylaxis Caput succedaneum Cholesterol embolus (warfarin blue toe syndrome) Cobb syndrome Corona phlebectatica Cryofibrinogenemic purpura Cryoglobulinemic purpura Cryoglobulinemic vasculitis Cutaneous small-vessel vasculitis (cutaneous leukocytoclastic angiitis, cutaneous leukocytoclastic vasculitis, cutaneous necrotizing venulitis, hypersensitivity angiitis) Deep venous thrombosis Disseminated intravascular coagulation Doucas and Kapetanakis pigmented purpura Drug-induced purpura Drug-induced thrombocytopenic purpura Eczematid-like purpura of Doucas and Kapetanakis Epidemic dropsy Erythema elevatum diutinum Erythromelalgia (acromelalgia, erythermalgia) Factitial lymphedema (hysterical edema) Fibrinolysis syndrome (defibrinating syndrome, hypofibrinogenemia) Food-induced purpura Generalized essential telangiectasia (general essential telangiectasia) Giant-cell arteritis Gougerot–Blum syndrome (pigmented purpuric lichenoid dermatitis, pigmented purpuric lichenoid dermatitis of Gougerot and Blum) Granulomatosis with polyangiitis Harlequin color change Hematopoietic ulcer Hennekam syndrome (Hennekam lymphangiectasia-lymphedema syndrome, intestinal lymphagiectasia-lymphedema-mental retardation syndrome) Henoch–Schönlein purpura (anaphylactoid purpura, purpura rheumatica, Schönlein–Henoch purpura) Hereditary hemorrhagic telangiectasia (Osler's disease, Osler–Weber–Rendu disease) Idiopathic thrombocytopenic purpura (autoimmune thrombocytopenic purpura, Werlhof's disease) IgA vasculitis Kawasaki's disease (mucocutaneous lymph node syndrome) Levamisole-induced vasculitis Lichen aureus (lichen purpuricus) Livedo racemosa Livedo reticularis Livedoid dermatitis (embolia cutis medicamentosa, Nicolau syndrome) Livedoid vasculopathy (atrophie blanche, livedo reticularis with summer ulceration, livedoid vasculitis, PURPLE syndrome, segmental hyalinizing vasculitis) Lymphedema praecox Lymphedema–distichiasis syndrome Maffucci syndrome Majocchi's disease (purpura annularis telangiectodes, purpura annularis telangiectodes of Majocchi) Malignant atrophic papulosis (Degos' disease) Marshall–White syndrome Meige lymphedema Microscopic polyangiitis (microscopic polyarteritis, microscopic polyarteritis nodosa) Mondor's disease (Mondor's syndrome of superficial thrombophlebitis) Neuropathic ulcer (mal perforans) Njolstad syndrome Nonne–Milroy–Meige syndrome (hereditary lymphedema, Milroy disease) Obstructive purpura Orthostatic purpura (stasis purpura) Painful bruising syndrome (autoerythrocyte sensitization, Gardner–Diamond syndrome, psychogenic purpura) Parkes Weber syndrome Paroxysmal hand hematoma (Achenbach syndrome) Paroxysmal nocturnal hemoglobinuria Polyarteritis nodosa (panarteritis nodosa, periarteritis nodosa) Postcardiotomy syndrome Perinatal gangrene of the buttock Pigmentary purpuric eruptions (progressive pigmentary dermatosis, progressive pigmenting purpura, purpura pigmentosa chronica) Postinflammatory lymphedema Postmastectomy lymphangiosarcoma (Stewart–Treves syndrome) Purpura fulminans (purpura gangrenosa) Purpura secondary to clotting disorders Purpuric agave dermatitis Raynaud phenomenon Raynaud's disease (primary Raynaud's phenomenon) Reactive angioendotheliomatosis Schamberg's disease (progressive pigmentary dermatosis of Schamberg, purpura pigmentosa progressiva, Schamberg's purpura) Secondary lymphedema Septic thrombophlebitis Sinusoidal hemangioma Sneddon's syndrome (idiopathic livedo reticularis with cerebrovascular accidents) Solar purpura (actinic purpura, senile purpura) Stasis dermatitis (congestion eczema, gravitational dermatitis, gravitational eczema, stasis eczema, varicose eczema) Superficial thrombophlebitis Takayasu arteritis (aortic arch syndrome, pulseless disease) Temporal arteritis (cranial arteritis, Horton's disease) Thromboangiitis obliterans (Buerger's disease) Thrombotic thrombocytopenic purpura (Moschcowitz syndrome) Traumatic purpura Trousseau's syndrome Unilateral nevoid telangiectasia (nevoid telangiectasia) Urticarial vasculitis (chronic urticaria as a manifestation of venulitis, hypocomplementemic urticarial vasculitis syndrome, hypocomplementemic vasculitis, unusual lupus-like syndrome) Venous insufficiency ulceration Waldenström hyperglobulinemic purpura (purpura hyperglobulinemica) Waldenström macroglobulinemia Yellow nail syndrome (primary lymphedema associated with yellow nails and pleural effusion)
In medieval Arabic literature, a longer penis was preferred, as described in an Arabian Nights tale called "Ali with the Large Member". As a witty satire of this fantasy, the 9th-century Afro-Arab author Al-Jahiz wrote: "If the length of the penis were a sign of honor, then the mule would belong to the Quraysh" (the tribe to which Muhammad belonged and from which he descended). The medieval Norsemen considered the size of a man's penis as the measure of his manliness, and a thirteenth-century Norse magic talisman from Bergen, a wooden stave inscribed in runic script, promises its wearer: "You will fuck Rannveig the Red. It will be bigger than a man's prick and smaller than a horse's prick." A late fourteenth century account of the life of Saint Óláfr from the Flateyjarbók describes a pagan ritual which centered around a preserved horse's penis used as a cult artifact which members of the cult would pass around in a circle, making up verses in praise of it, encouraging it and the other members of the group to behave in sexually suggestive ways. During the Renaissance, some men in Europe began to wear codpieces, which accentuated their genitals. There is no direct evidence that it was worn to enhance the apparent size of the wearer's penis, but larger codpieces were seen as more fashionable.
Sources: en.wikipedia.org
Artificially created antimatter is usable only as an energy storage medium, not as an energy source, unless future technological developments (contrary to the conservation of the baryon number, such as a CP violation in favor of antimatter) allow the conversion of ordinary matter into anti-matter. Theoretically, humans may be able to cultivate and harvest a number of naturally occurring sources of antimatter in the future. Renewable energy by converting sunlight into electricity – either directly through solar cells and concentrating solar power, or indirectly through biofuels, wind, and hydroelectric power: There is no known way for a human civilization to harness the equivalent of the Earth's total absorbed solar energy without completely covering the surface with man-made structures, which is not feasible with current technology. However, if a civilization constructed very large space-based solar power satellites, Type I power levels might become achievable—these could convert sunlight to microwave power and beam it to collectors on Earth.
Clinically, the diagnosis of any particular skin condition is made by gathering pertinent information regarding the presenting skin lesion(s), including the location (such as arms, head, legs), symptoms (pruritus, pain), duration (acute or chronic), arrangement (solitary, generalized, annular, linear), morphology (macules, papules, vesicles), and color (red, blue, brown, black, white, yellow). Diagnosis of many conditions often also requires a skin biopsy which yields histologic information that can be correlated with the clinical presentation and any laboratory data.
=== Recreational === MDMA is often considered the drug of choice within the rave culture and is also used at clubs, festivals, and house parties. In the rave environment, the sensory effects of music and lighting are often highly synergistic with the drug. The psychedelic amphetamine quality of MDMA offers multiple appealing aspects to users in the rave setting. Some users enjoy the feeling of mass communion from the inhibition-reducing effects of the drug, while others use it as party fuel because of the drug's stimulatory effects. MDMA is used less often than other stimulants, typically less than once per week. MDMA is sometimes taken in conjunction with other psychoactive drugs such as LSD, psilocybin mushrooms, 2C-B, and ketamine. The combination with LSD is called "candy-flipping". The combination with 2C-B is called "nexus flipping". For this combination, most people take the MDMA first, wait until the peak is over, and then take the 2C-B. MDMA is often co-administered with alcohol, methamphetamine, and prescription drugs such as SSRIs with which MDMA has several drug-drug interactions. Three life-threatening reports of MDMA co-administration with ritonavir have been reported; with ritonavir having severe and dangerous drug-drug interactions with a wide range of both psychoactive, anti-psychotic, and non-psychoactive drugs.
Sources: en.wikipedia.org
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.
Early development used the albumin-binding form, and a shorter variant was later discussed under the same label. Because the two differ in half-life and handling, ambiguity arises whenever a source omits the variant designation.
The compound derives from that fragment but is not identical to it. The parent fragment lacks the stabilizing substitutions, so its degradation rate and duration of action differ noticeably.
It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.